Retracted: "Oxidative damage of 14-3-3 zeta and gamma isoforms in Alzheimer's disease and cerebral amyloid angiopathy" [Neuroscience 146 (2007) 1640-1651] (DOI:10.1016/j.neuroscience.2007.03.013);Oxidative damage of 14-3-3 zeta and gamma isoforms in Alzheimer's disease and cerebral amyloid angiopathy

Neuroscience

Volumn 146, Issue 4, 2007, Pages 1640-1651

  Santpere, G ^a   Puig, B ^a   Ferrer, I ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

14 3 3; Alzheimer's disease; A ; cerebral amyloid angiopathy; lipoxidation; oxidative stress

Indexed keywords

4 HYDROXYNONENAL; MALONALDEHYDE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVATION; FRONTAL CORTEX; GEL ELECTROPHORESIS; HUMAN; MASS SPECTROMETRY; OXIDATION; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS; WESTERN BLOTTING;

EID: 34249314785     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.05.001     Document Type: Erratum

References (55)

1. Agarwal-Mawal A., Qureshi H.Y., Cafferty P.W., Yuan Z., Han D., Lin R., and Paudel H.K. 14-3-3 Connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. J Biol Chem 278 (2003) 12722-12728
2. Aitken A. 14-3-3 Proteins: a historic overview. Semin Cancer Biol 16 (2006) 162-172
3. Atzori C., Ghetti B., Piva R., Srinivasan A.N., Zolo P., Delisle M.B., Mirra S.S., and Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 60 (2001) 1190-1197
4. Avila J., Lim F., Moreno F., Belmonte C., and Cuello A.C. Tau function and dysfunction in neurons: its role in neurodegenerative disorders. Mol Neurobiol 25 (2002) 213-231
5. Berg D., Holzmann C., and Riess O. 14-3-3 Proteins in the nervous system. Nat Rev Neurosci 4 (2003) 752-762
6. Boyd-Kimball D., Sultana R., Fai Poon H., Lynn B.C., Casamenti F., Pepeu G., Klein J.B., and Butterfield D.A. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid β-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 132 (2005) 313-324
7. Braak H., and Braak E. Temporal sequence of Alzheimer's disease-related pathology. In: Peters A., and Morrison J.H. (Eds). Cerebral cortex, Vol. 14: Neurodegenerative and age-related changes in structure and function of cerebral cortex (1999), Kluwer Academic/Plenum Press, New York 475-512
8. Bridges D., and Moorhead G.B. 14-3-3 Proteins: a number of functions for a numbered protein. Sci STKE (2005) 2005: re10
9. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., and Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33 (2000) 95-130
10. Butterfield D.A. Amyloid beta-peptide (1-42)-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr Med Chem 10 (2003) 2651-2659
11. Butterfield D.A., Drake J., Pocernich C., and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for β-amyloid peptide. Trends Mol Med 7 (2001) 548-554
12. Butterfield D.A., and Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Rad Biol Med 32 (2002) 1050-1060
13. Butterfield D.A., Perluigi M., and Sultana R. Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics. Eur J Pharmacol 545 (2006) 39-50
14. Cecchi C., Fiorillo C., Sorbi S., Latorraca S., Nacmias B., Bagnoli S., Nassi P., and Liguri G. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 33 (2002) 1372-1379
15. Chauhan V., and Chauhan A. Oxidative stress in Alzheimer's disease. Pathophysiology 3 (2006) 195-208
16. Coblitz B., Wu M., Shikano S., and Li M. C-terminal binding: an expanded repertoire and function of 14-3-3 proteins. FEBS Lett 580 (2006) 1531-1535
17. Darling D.L., Yingling J., and Wynshaw-Boris A. Role of 14-3-3 proteins in eukaryotic signaling and development. Curr Top Dev Biol 68 (2005) 281-315
18. Davies K.J. Degradation of oxidized proteins by the 20S proteasome. Biochimie 83 (2001) 301-310
19. Davies K.J. Protein damage and degradation by oxygen radicals. I. general aspects. J Biol Chem 262 (1987) 9895-9901
20. Dougherty M.K., and Morrison D.K. Unlocking the code 14-3-3. J Cell Sci 117 (2004) 1875-1884
21. Drake J., Link C.D., and Butterfied D.A. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide1-42 in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24 (2003) 415-420
22. Duyckaerts C., and Dickson D.W. Neuropathology of Alzheimer's disease. In: Dickson D. (Ed). Neurodegeneration: the molecular pathology of dementia and movement disorders (2003), ISN Neuropath Press, Basel 47-68
23. Ferl R.J. 14-3-3 proteins and signal transduction. Annu Rev Plant Physiol Plant Mol Biol 47 (1996) 49-73
24. Ferrer I., Blanco R., Carmona M., and Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 108 (2001) 1397-1415
25. Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribe E., Dalfó E., and Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2 (2005) 3-18
26. Fountoulakis M., Cairns N., and Lubec G. Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 57 (1999) 323-335
27. Fu R.R., and Subramanian S.C. Masters, 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40 (2000) 617-647
28. Garrison W.M., Jayko M.E., and Bennet W. Radiation-induced oxidation of protein in aqueous solution. Radiat Res 16 (1962) 483-502
29. Hashiguchi M., Sobue K., and Paudel H.K. 14-3-3 Zeta is an effector of tau protein phosphorylation. J Biol Chem 275 (2000) 25247-25254
30. Hermeking H., and Benzinger A. 14-3-3 Proteins in cell cycle regulation. Semin Cancer Biol 16 (2006) 183-192
31. Hernández F., Cuadros R., and Avila J. Zeta 14-3-3 protein favors the formation of human tau fibrillar polymers. Neurosci Lett 357 (2004) 143-146
32. Layfield R., Fergusson J., Aitken A., Lowe J., Landon M., and Mayer R.J. Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci Lett 209 (1996) 57-60
33. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 24 (2001) 1121-1159
34. Masters C.L., and Beyreuther K. Molecular pathogenesis of Alzheimer's disease. In: Dickson D. (Ed). Neurodegeneration: the molecular pathology of dementia and movement disorders (2003), ISN Neuropath Press, Basel 69-73
35. Mhawech P. 14-3-3 Proteins. An update. Cell Res 15 (2005) 228-236
36. Muñoz F.J., Sole M., and Coma M. The protective role of vitamin E in vascular amyloid beta-mediated damage. Subcell Biochem 38 (2005) 147-165
37. Muslin A.J., and Lau J.M. Differential functions of 14-3-3 isoforms in vertebrate development. Curr Top Dev Biol 65 (2005) 211-228
38. Nishikawa K., Li H., Kawamura R., Osaka H., Wang Y.L., Hara Y., Hirokawa T., Manago Y., Amano T., Noda M., Aoki S., and Wada K. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 304 (2003) 176-183
39. Nunomura A., Castellani R.J., Zhu X., Moreira P.I., Perry G., and Smith M.A. Involvement of oxidative stress in Alzheimer's disease. J Neuropathol Exp Neurol 65 (2006) 631-641
40. Oliver C.N., Ahn B.W., Moerman E.J., Goldstein S., and Stadtman E.R. Age-related changes in oxidized proteins. J Biol Chem 262 (1987) 5488-5491
41. Pamplona R., Dalfó E., Ayala V., Bellmunt J., Prat J., Ferrer I., and Portero M. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 280 (2005) 21522-21530
42. Pei J.J., Braak E., Braak H., Grundque-Iqbal K., Winblad W., and Cowburn R.F. Localization of active forms of c-Jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimer's Dis 3 (2001) 41-48
43. Puig B., Gómez-Isla T., Ribé E., Cuadrado M., Torrejón-Escribano B., Dalfó E., and Ferrer I. Expression of stress-activated kinase c-Jun N-terminal kinase (SAPK/JNK-P) and p38 (p38-P), and tau hyperphosphorylation in neurites surrounding βA plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol 30 (2004) 491-502
44. Richard M., Biacabe A.G., Streichenberger N., Ironside J.W., Mohr M., Kopp N., and Perret-Liaudet A. Immunohistochemical localization of 14-3-3 zeta protein in amyloid plaques in human spongiform encephalopathies. Acta Neuropathol 105 (2003) 296-302
45. Sergeant N., Delacourte A., and Buee L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 1739 (2005) 179-197
46. Soulié C., Nicole A., Delacourte A., and Ceballos-Picot I. Examination of stress-related genes in human temporal versus occipital cortex in the course of neurodegeneration: involvement of 14-3-3 zeta in this dynamic process. Neurosci Lett 365 (2004) 1-5
47. Spillantini M.G., and Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 21 (1998) 428-433
48. Sultana R., Newman S.F., Mohammad Abdul H., Cai J., Pierce W.M., Klein J.B., Merchant M., and Butterfield D.A. Protective effect of D609 against amyloid-beta1-42-induced oxidative modifications of neuronal proteins: redox proteomics study. J Neurosci Res 84 (2006) 409-417
49. Takahashi Y. The 14-3-3 proteins: gene, gene expression, and function. Neurochem Res 28 (2003) 1265-1273
50. Umahara T., Uchihara T., Tsuchiya K., Nakamura A., Iwamoto T., Ikeda K., and Takasaki M. 14-3-3 Proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathol 108 (2004) 279-286
51. van Heusden G.P. 14-3-3 Proteins: regulators of numerous eukaryotic proteins. IUBMB Life 57 (2005) 623-629
52. Varadarajan S., Yatin S., Aksenova M., and Butterfield D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130 (2000) 184-208
53. Yuan Z., Agarwal-Marwal A., and Paudel H.K. 14-3-3 binds to and mediates phosphorylation of microtubule-associated tau protein by Ser9-phosphorylated glycogen synthase kinase 3β in the brain. J Biol Chem 279 (2004) 26105-26114
54. Zhu X., Raina A.K., Rottkamp C.A., Aliev G., Perry G., Boux H., and Smith M.A. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 76 (2001) 435-441
55. Zhu X., Rottkamp C.A., Boux H., Takeda A., Perry G., and Smith M.A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59 (2000) 880-888